Cancer research has entered the age of molecular therapeutics. Medicine is now rationally designed to target crucial molecular aberrations of cancer or use specific cancer cell behaviour. Translational research in early clinical trials is a critical aspect of the development of the new generation of cancer drugs. Through clinical research, the implementation of radically different early phase clinical trial designs or the validation of new biological end-points can be achieved. This BRIO program relies first on two phase-1 clinical trial units based at the University Hospital Centre of Bordeaux and Bergonié Institute respectively and recognized as reference centres by the French National Cancer Institute. Through this program, cancer patients and referring physicians from the Aquitaine region, but also from regions associated in the Canceropôle Grand Sud-Ouest already have access to the newest and most promising targeted anti-cancer treatments supported by academic institutions or pharmaceutical companies.
Due to their translational status, all SIRIC programs are expected to feed or support the pipeline of new therapeutics. To ensure continuity and local innovation, BRIO aims to develop specific projects based on novel mechanism, discovery of resistance mechanism of previously used drugs or new technologies.
Under the supervision of Dr A. Italiano (Bergonié Institute), this collaborative initiative brings together interdisciplinary research teams of scientists and health professionals to research and develop new cures, while providing a continuum of care for patients :
This BRIO program focuses on three main areas :
- Development and implementation of industry-sponsored or academic proof of concept early clinical trials.
- Translational research focusing on the identification of predictive biomarkers and mechanisms of resistance to innovative anti-cancer therapies.
- Development of powerful and innovative imaging tools to assess the tumour response.